Oral prostaglandin E1 derivative (OP-1206) in an infant with double outlet right ventricle and pulmonary stenosis. Effect on ductus-dependent pulmonary circulation.

Abstract

A small-for-gestational-age infant with cyanosis due to double outlet right ventricle with severe pulmonary stenosis and patent ductus arteriosus was treated with oral prostaglandin E1 derivative (OP-1206). The constricting ductus arteriosus dilated and the ductus-dependent pulmonary blood flow increased. The recommended dosage was 1.5-2.0 micrograms/kg/day which was lower than that of intravenous PGE1 or of oral PGE2. The administration interval was 6 hours, which was longer than that of oral PGE2. The patient was treated as an out-patient because continuous intravenous infusion was not necessary. Treatment was continued for 2 months without complication, at which time a Blalock-Taussig shunt operation was performed. Orally administered PGE1 derivative (OP-1206) was found to be equally effective to intravenous infusion of PGE1 for both short and long-term management of cyanotic heart disease in which the pulmonary blood flow is mostly dependent on the patency of the ductus arteriosus. Oral PGE1 derivative (OP-1206) may be a possible substitute for intravenous PGE1 infusion therapy.

• Authors: T Saji, H Matsuura, K Hoshino, S Yamamoto, T Ishikita, N Matsuo
• Journal: Japanese heart journal (Jpn Heart J) Vol. 32 Issue 5 Pg. 735-40 (Sep 1991) ISSN: 0021-4868 [Print] Japan
• PMID: 1774835 (Publication Type: Case Reports, Journal Article)

Chemical References

• Vasodilator Agents
• ONO 1206
• Alprostadil

Topics

• Administration, Oral
• Alprostadil (administration & dosage, analogs & derivatives)
• Double Outlet Right Ventricle (complications)
• Ductus Arteriosus, Patent (complications, drug therapy, physiopathology)
• Humans
• Infant, Newborn
• Male
• Pulmonary Circulation (drug effects)
• Pulmonary Valve Stenosis (complications, congenital)
• Vasodilator Agents (administration & dosage)